



CASE PA/4-32394A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 106 064 119 US

Express Mail Label Number

July 9, 2008

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1618

KARNACHI ET AL.

Examiner: Nabila G. Ebrahim

APPLICATION NO: 10/506,821

FILED: SEPTEMBER 7, 2004

FOR: SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING
LUMIRACOXIB

MS: After Final

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

NOTICE OF APPEAL
PETITION FOR EXTENSION OF TIME

Sir:

The period for filing a Notice of Appeal has a shortened statutory time set to expire on June 21, 2008. A one-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$120 for payment of the extension fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080

Date: July 9, 2008

Jennifer C. Chapman
Jennifer C. Chapman
Attorney for Applicants
Reg. No. 47,487
Phone No. (862) 778-1202

07/11/2008 MGBREM1 00000046 190134 10506021

02 FC:1251

120.00 DA



CASE PA/4-32394A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
<u>EV 706 064 119 US</u> Express Mail Label Number	<u>July 9, 2008</u> Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1618

KARNACHI ET AL.

Examiner: Nabila G. Ebrahim

APPLICATION NO: 10/506,821

FILED: SEPTEMBER 7, 2004

FOR: SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING
LUMIRACOXIB

MS: After Final
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

NOTICE OF APPEAL
PETITION FOR EXTENSION OF TIME

Sir:

The period for filing a Notice of Appeal has a shortened statutory time set to expire on June 21, 2008. A one-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$120 for payment of the extension fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080

Date: July 9, 2008

Jennifer C. Chapman
Jennifer C. Chapman
Attorney for Applicants
Reg. No. 47,487
Phone No. (862) 778-1202